Low-dose melphalan for treatment of high-risk myelodysplastic syndromes.

Omoto, E; Deguchi, S; Takaba, S; Kojima, K; Yano, T; Katayama, Y; Sunami, K; Takeuchi, M; Kimura, F; Harada, M; Kimura, I

Omoto, E; Deguchi, S; Takaba, S; Kojima, K; Yano, T; Katayama, Y; Sunami, K; Takeuchi, M; Kimura, F; Harada, M; Kimura, I.

Affiliation

Omoto E; Department of Medicine II, Okayama University Medical School, Okayama City, Japan.

Leukemia ; 10(4): 609-14, 1996 Apr.

Article in En | MEDLINE | ID: mdl-8618435

Subject(s)

Anemia, Refractory/drug therapy; Antineoplastic Agents, Alkylating/therapeutic use; Melphalan/therapeutic use; Aged; Aged, 80 and over; Anemia, Refractory/blood; Anemia, Refractory/pathology; Blood Transfusion; Bone Marrow/pathology; Disease-Free Survival; Erythrocyte Count; Female; Follow-Up Studies; Hemoglobins/analysis; Humans; Leukocyte Count; Male; Middle Aged; Platelet Count; Remission Induction; Risk Factors; Time Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Anemia, Refractory / Antineoplastic Agents, Alkylating / Melphalan Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 1996 Type: Article Affiliation country: Japan

Search on Google

XML

PubMed Links